Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...

England’s drug approval body has resisted pressure from pharmaceutical companies to loosen its process for recommending drugs and is pressing instead for the NHS to speed up the rollout of approved ...

During a live event, Xiuning Le, MD, PhD, discussed clinical trials of supportive care for infusion reaction and skin rash ...

Press Release Top decision-makers from across the biopharma ecosystem will convene in Chicago for the 2nd BioCentury Grand Rounds – U.S., at the intersection of research, investment and drug ...

Daiichi Sankyo has been ordered to pay an 8% royalty rate on sales of AstraZeneca-partnered breast and gastric cancer therapy Enhertu (trastuzumab deruxtecan) after Seagen won a lawsuit claiming ...

Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...

AstraZeneca has enlisted the help of Lilly in the development of its new Alzheimer's candidate AZD3293. The drug is an oral beta secretase cleaving enzyme (BACE) inhibitor, which the companies ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 20,473.75 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key ...